Current Practices in Myocardial Perfusion Scintigraphy in Brazil and Adherence to
            the IAEA Recommendations: Results of a Cross-Sectional Study

Rodrigues, Carlos Vitor Braga; Oliveira, Anderson Eduardo Carvalho de; Wiefels, Christiane; Leão, Maurício de Souza; Mesquita, Cláudio Tinoco

doi:10.5935/abc.20180023

Cited by 2 publications

(2 citation statements)

References 21 publications

(26 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Each patient included in the study gave informed consent to perform pharmacological stress SPECT. The exclusion criteria were the contraindications to the pharmacological stress with vasodilators (a history of severe bronchospasm, asthma during physical activity, severe aortic stenosis, severe obstructive hypertrophic cardiomyopathy, pregnancy or lactation, 2° or 3° degree, atrioventricular block and atrial node disease, arterial hypotension (SP <90 mmHg), or history of allergic reaction to the previously mentioned drugs) ( 7 ). The collected data included the characteristics of the patients such as sex, age, body mass index (BMI), medical information regarding chronic diseases like diabetes, hypertension, atherosclerosis, hyperlipidemia as well as past myocardial infarction (MI) or heart failure and the history of medical procedures [percutaneous coronary interventions (PCI), and coronary artery bypass graft surgery (CABG)] as well as information regarding to the stress MPI procedure: side effects (divided into mild: headache, vertigo, nausea, vomiting, dyspnea, chest discomfort, hot flushes, overall weakness, and severe: bradycardia (defined as heart rate below 60), hypotension [defined as systolic blood pressure (SBP), <90 or mean blood pressure (MBP) <70 and loss of consciousness] and blood pressure measurements: before the procedure, 5 times during the procedure (every minute) and 4 times after the procedure (every minute).…”

Section: Methodsmentioning

confidence: 99%

Comparison of Regadenoson and Dipyridamole Safety Profiles During Stress Myocardial Perfusion Imaging

Roczniak¹,

Bączalska²,

Kanclerz³

et al. 2023

Mirt

View full text Add to dashboard Cite

Objectives: The pharmacological stress test with vasodilator agents is an alternative cardiological diagnostic tool for patients with contraindications to the classical stress test provided by physical activity during single-photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI). The study compared the frequency of the side effects of regadenoson and dipyridamole during a SPECT MPI. Methods: This retrospective study included data of 283 consecutive patients who underwent pharmacological stress tests in years 2015-2020. The study group consisted of 240 patients who had received dipyridamole and 43 patients who had received regadenoson. The collected data included the patients’ characteristics, the occurrence of side effects (divided into mild: headache, vertigo, nausea, vomiting, dyspnea, chest discomfort, hot flushes, general weakness and severe: bradycardia, hypotension, loss of consciousness), and blood pressure values/measurements. Results: Overall, complications occurred relatively often (regadenoson: 23.2%, dipirydamol: 26.7%, p=0.639). Procedure discontinuation was necessary in 0.7% of examinations, whereas pharmacological support was necessary in 4.7%. There was no difference in the prevalence of mild (regadenoson: 16.2%, dipirydamol: 18.3%, p=0.747) and severe complications (regadenoson: 11.6%, dipyridamole: 15.0%, p=0.563). However, regadenoson has been found to cause a significantly smaller mean decrease of systolic blood pressure (SBP) (regadenoson: -2.6±10.0 mmHg, dipyridamole: -8.7±9.6 mmHg, p=0.002), diastolic blood pressure (DBP) (regadenoson: -0.9±5.4 mmHg, dipyridamole: -3.6±6.2 mmHg, p=0.032), as well as mean arterial pressure (MAP) (regadenoson: -1.5±5.6 mmHg, dipyridamole: -5.4±6.5 mmHg, p=0.001). Conclusion: Regadenoson and dipyridamole presented a similar safety profile during SPECT MPI. However, regadenoson has been found to cause significantly smaller decreases in SBP, DBP, and MAP.

show abstract

Section: Methodsmentioning

confidence: 99%

Comparison of Regadenoson and Dipyridamole Safety Profiles During Stress Myocardial Perfusion Imaging

Roczniak¹,

Bączalska²,

Kanclerz³

et al. 2023

Mirt

View full text Add to dashboard Cite

show abstract

“…Data about the presence of present a higher risk for adverse outcomes than those with a normal test. 19,20…”

Section: Study Samplementioning

confidence: 99%

Is Trimethylamine N-oxide (TMAO) Associated with NF-κB mRNA Expression in Patients with Coronary Artery Disease?

Cruz,

Coutinho-Wolino,

Cardozo

et al. 2024

International Journal of Cardiovascular Sciences

View full text Add to dashboard Cite

Background: Trimethylamine N-oxide (TMAO), a gut microbiota metabolite, is associated with cardiovascular disease (CVD) development. TMAO can trigger an inflammatory response by inducing the nuclear factor-kappa B (NF-κB) signaling cascade and increasing the expression of pro-inflammatory cytokines, contributing to the worsening of CVD. This study aimed to evaluate the association between TMAO plasma levels and inflammation in patients with coronary artery disease (CAD). Methods:A cross-sectional study was carried out including 29 patients with CAD. Peripheral blood mononuclear cells (PBMC) were isolated from fasting blood samples, and NF-κB and vascular cell adhesion protein 1 (VCAM1) mRNA expression were estimated using real-time quantitative PCR. We determined TMAO plasma levels by LC-MS/MS and TNF-α by ELISA. Routine biochemical parameters were evaluated using an automatic biochemical analyzer. Correlations were estimated by Spearman or Pearson test. Statistical significance was set at the level of p < 0.05. Results:All patients presented TMAO levels within the normal range according to EUTox (normal range: 2.83 ± 1.53 mg/L; CAD patients: 0.2 [0.1 to 0.2] ng/μL). TMAO plasma levels were positively correlated with NF-κB mRNA expression (0.555; p = 0.002). Conclusion:TMAO plasma levels may be associated with NF-κB mRNA expression in patients with CAD and may contribute to the pathogenesis of this disease.

show abstract

Current Practices in Myocardial Perfusion Scintigraphy in Brazil and Adherence to the IAEA Recommendations: Results of a Cross-Sectional Study

Cited by 2 publications

References 21 publications

Comparison of Regadenoson and Dipyridamole Safety Profiles During Stress Myocardial Perfusion Imaging

Comparison of Regadenoson and Dipyridamole Safety Profiles During Stress Myocardial Perfusion Imaging

Is Trimethylamine N-oxide (TMAO) Associated with NF-κB mRNA Expression in Patients with Coronary Artery Disease?

Contact Info

Product

Resources

About